Novel Patented Src Kinase Inhibitor

Author(s): Xiao-Ling Lu, Xiao-Yu Liu, Xin Cao, Bing-Hua Jiao

Journal Name: Current Medicinal Chemistry

Volume 19 , Issue 12 , 2012

Become EABM
Become Reviewer
Call for Editor


Src family of protein tyrosine kinases (SFKs) plays key roles in the regulation of signal transductions in cellular processes. However, hyper-activated SFKs lead to uncontrolled cell proliferation and cancers. Src-targeted compounds were developed to block the cell proliferation signal transductions for cancer therapy. Src kinase domain inhibitors were designed, synthesized and evaluated as anticancer agents, while the patents applied at the same time. Great progress has been made in the Src kinase inhibitor area. Herein, some predominant patents about Src kinase inhibitors of the recent years are reviewed.

Keywords: Anticancer, AZD-0530, BMS-354825, carcinogenesis, inhibitor, kinase domain, SKI-606, Src kinase

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [1821 - 1829]
Pages: 9
DOI: 10.2174/092986712800099802
Price: $65

Article Metrics

PDF: 28